Lexaria Announces 2023 Annual Meeting Results

About this update from Lexaria Bioscience Corp.

[{"type":"text","content":"KELOWNA, BC / ACCESSWIRE / May 10, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces the results of the 2023 Annual Meeting (the \"Meeting\").On May 9, 2023 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 3,372,024 shares of the Company represented in person or by proxy at the meeting, constituting 56.3% of the Company's issued share capital as at March 13, 2023, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:Matter Being Voted OnForAgainst/WithheldAbstainBroker Non-VotePercent Approved By1To Elect Chris Bunka as a director2,141,96477,489 1,152,57196.5%To Elect John Docherty as a director2,137,54681,907 1,152,57196.3%To Elect Nicholas Baxter as a director1,648,288571,165 1,152,57174.3%To Elect Ted McKechnie as a director2,123,86995,584 1,152,57195.7%To Elect Albert Reese Jr. as a director2,134,83784,683 1,152,50496.2%To Elect Dr. Catherine Turkel as a director2,165,42654,027 1,152,57197.6%To Appoint Malone Bailey LLP as Auditors3,249,199105,06717,758 96.4%To Approve the Stock Option Repricing1,529,271677,68612,4291,152,63868.9%To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan1,965,779249,5194,1551,152,57188.6%To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan1,400,723709,940108,7901,152,57163.1%To Ratify the lawful actions of the directors for the past year2,005,926156,38257,1451,152,57190.4%1 Percentage is calculated based on abstained votes being counted as a vote against the resolutionAll of the proposals are described in detail in the Company's proxy statement filed with the Securities Exchange Commission via Edgar and with the BC Securities Commission and Ontario Securities Commission via SEDAR on March 22, 2023.About Lexaria Bioscience Corp.Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effective...

More updates from Lexaria Bioscience Corp.